On This Day in Health: March 2, 1985
On March 2, 1985, the United States Food and Drug Administration licensed the first commercial blood test for antibodies to the virus that causes AIDS. Developed by Abbott Laboratories, the test was authorized to screen blood and plasma intended for transfusion or manufacture into other products. The virus was then commonly described as HTLV-III or LAV; the name HIV became standard later. The decision gave blood services a practical tool for detecting evidence of infection before a donation reached a recipient. It was a pivotal response to an epidemic that had exposed frightening gaps in knowledge, prevention, and the safety of the blood supply.
The assay used an enzyme-linked immunosorbent technique, generally known as ELISA. It looked for the immune system's antibodies rather than directly counting the virus. In the early kit, viral proteins provided a surface to which relevant antibodies could attach, and a chemical reaction made that attachment detectable. Such laboratory methods transformed a biological response into a signal that could be interpreted and checked. A reactive screening result nevertheless required careful handling; it was not equivalent to a diagnosis of AIDS. The difference between identifying infection and diagnosing the syndrome was especially important when public discussion often collapsed both into the same phrase.
Testing soon moved beyond the blood-bank setting. Federal support helped state and local health departments establish alternate sites where people could seek testing without donating blood. These services linked laboratory work with counseling and referral, recognizing that results could carry profound personal consequences. Confidentiality mattered in an atmosphere of fear and discrimination. By the end of 1985, hundreds of alternate sites were operating, but establishing them had required staffing, administrative arrangements, and systems to protect records. This history shows why a newly licensed test does not instantly become an accessible service. Its public value depends on where testing is available and whether people trust the process enough to use it.
Over subsequent decades, HIV testing became faster, more varied, and more closely connected with effective treatment. Those later developments should not be projected backward onto the first authorization. The 1985 test represented an early turning point, with limitations associated with antibody detection and the interval before antibodies became measurable. It did not eliminate every risk or resolve the social obstacles surrounding HIV. March 2 is remembered because a research breakthrough became a usable screening tool at a moment of urgent need. Its lasting significance reaches beyond the laboratory: the history connects safer transfusion, knowledge of infection status, protection of privacy, and the continuing effort to make diagnosis a doorway to care rather than a source of exclusion.
The first authorization focused on donated blood and plasma. It offered a new way to reduce transmission through transfusion and manufactured blood products.
HTLV-III and LAV were names used before HIV became standard. Historical terminology can otherwise make the first test seem unrelated to modern HIV diagnostics.
An antibody screening assay detects an immune response. A reactive result and a diagnosis of AIDS are different findings.
Alternate testing sites connected laboratory services with counseling and referral. They allowed people to seek testing outside blood donation settings.
Confidentiality and trust shaped whether people used the new services. A technical advance needed an accessible and credible public health system around it.
Later tests and treatments changed what diagnosis could offer. Those improvements followed the 1985 milestone rather than forming part of its original capabilities.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.